MedTrace Logo

Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder

NCT01664260 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-02-09

No results posted yet for this study

Summary

It has been suggested that N-acetylcysteine exerts neuroprotective effects by regulating neurotransmitters and cell signaling pathways. We hypothesize that oral N-acetylcysteine augmentation will help reduce symptoms in patients with posttraumatic stress disorder as well as improve cognitive functions. We also expect that the N-acetylcysteine augmentation will induce change in structural, functional, and neurochemical aspects of the brain.

In this study, we plan to conduct a randomized, double-blind, placebo-controlled augmentation study with N-acetylcysteine in addition to escitalopram. We will assess the efficacy and safety of the N-acetylcysteine augmentation.

Conditions

Interventions

DRUG

N-acetylcysteine

0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day

DRUG

Placebo

0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day

Sponsors & Collaborators

  • Ewha Womans University

    lead OTHER

Principal Investigators

  • Inkyoon Lyoo, MD, PhD, MMS · Ewha Womans University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-01
Primary Completion
2016-12-01
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01664260 on ClinicalTrials.gov